Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a cancer with dismal prognosis due to resistance to most current therapies. Although immunotherapy has improved the treatment of many solid cancers, pancreatic cancer remains resistant to immunotherapy due to immunosuppressive tumor microenvironmen...

Full description

Bibliographic Details

Published in:	Cancer Immunology, Immunotherapy
Main Authors:	Santeri A. Pakola, Nea Ojala, Tatiana V. Kudling, James H. A. Clubb, Elise Jirovec, Mirte van der Heijden, Victor Arias, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Dafne C. A. Quixabeira, Joao M. Santos, Victor Cervera-Carrascon, Otto Hemminki, Anna Kanerva, Harri Mustonen, Pauli Puolakkainen, Hanna Seppänen, Akseli Hemminki
Format:	Article
Language:	English
Published:	Springer 2025-06-01
Subjects:	Oncolytic virus Adenovirus, Pancreatic cancer Immunotherapy PD-L1 Checkpoint inhibitor
Online Access:	https://doi.org/10.1007/s00262-025-04072-6